AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05502081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casirivimab and Imdevimab Drug Combination
Description: antiviral Monoclonal Antibodies
Study NCT05238207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-001
Description: Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion
Study NCT05238207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Original Fibre Metamucil
Description: Part A: 1 dose placebo administered in a crossover fashion Part B: 2 doses placebo administered in a crossover fashion
Study NCT06478316 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intracervical block
Description: local injection of lidocain to the cervix
Study NCT06478316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracervical block
Description: local injection of lidocain to the cervix
Study NCT06361394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness course
Description: The experimental group will enroll in the elective course named Mindfulness and Happiness, which will consist of 2 hours every week for a continuous period of 18 weeks. The comparison group will not participate in this course.
Study NCT04189965 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Validation of virtual environment and auditive stimulation with virtual reality glasses (Pilot phase)
Description: The goal of this phase is the development of the experimental protocol in virtual reality. Virtual environment will be checked and auditive stimulation will be graduated.
Study NCT04189965 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrical cutaneous stimulation and auditive stimulation (Principal Experimental phase)
Description: This phase is the principal step of the study: during moving in virtual environment, electrical stimulation on one hand and auditive stimulation will be applied. EEG, ECG and skin conductance will be measured during conditioning phase and extinction phase (day 1, 30 minutes each phase). Behavioral measures will be done throughout the 3 sessions (day 1, day 2 and day 30)
Study NCT04189965 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrical cutaneous stimulation and auditive stimulation (Secondary Experimental phase)
Description: This phase is the same of the Principal Experimental phase except for the EEG that will not be performed.
Study NCT06005818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab injection
Description: PD-1 antibody
Study NCT06796725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: (1) The patient undergoes pseudo stimulus intervention in the first week and real stimulus intervention afterwards, which is blind to the patient. (2) Starting from the second week, true stimulation intervention will be conducted for 4 weeks, with each patient making an appointment for 1 month. On Day 7 after the patient intervention, Day 14, Day 30, Day 60, Day 90, Day 180 scales were used to evaluate follow-up.
Study NCT06796725 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sibelium
Description: Sibelium 10mg is taken orally every night for 4 weeks each course of treatment. Patients were evaluated and followed up with a scale based on medication intervention, including Day 7, Day 14, Day 30, Day 60, Day 90, and Day 180
Study NCT06796322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive blood glucose meter
Description: Blood glucose were detected by non-invasive glucose meter at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
Study NCT06796322 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: fully automatic laboratory biochemical analyzer
Description: Blood glucose were detected by fully automatic laboratory biochemical analyzer using plasma sample at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
Study NCT06796322 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: fingertip capillary blood glucose meter
Description: Blood glucose were detected by fingertip capillary blood sample at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
Study NCT06794567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: Early access to genetic testing.
Study NCT06793267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide (Maxolon)
Description: Participants will receive 0.15 mg/kg of metoclopramide administered intravenously. The drug will be diluted in 2 ml of solution prior to administration.
Study NCT06793267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: patients will recive normal saline 0.9% 2ml intravenous
Study NCT06793189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab and Orelabrutinib
Description: Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days) and Orelabrutinib (150 mg once daily).
Study NCT06793189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab, Orelabrutinib and Lenalidomide
Description: Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days), Orelabrutinib (150 mg once daily), and Lenalidomide (25 mg on days 2-11 of cycles 1-6, cycle length=21 days).
Study NCT06793189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Maintenance: Orelabrutinib monotherapy (150 mg once daily up to 24 months).
Study NCT06797180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Education for Dementia Caregivers
Description: This group will receive 100 minutes of BPSD foundational education followed by 100 minutes of VR-based training focused on managing BPSD.
Study NCT06794268 — intervention group
Intervention type: BIOLOGICAL
Intervention: Lisocabtagene maraleucel
Description: As per product label
Study NCT06793072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Leptin concentration in blood serum
Description: Fasting plasma leptin concentration measurement with results expressed in pg/ml and comparison across all study arms
Study NCT06793072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Resistin concentration in blood serum
Description: Fasting plasma resistin concentration measurement with results expressed in pg/ml and comparison across all study arms
Study NCT06793072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Omentin-1 concentration in blood serum
Description: Fasting plasma omentin-1 concentration measurement with results expressed in pg/ml and comparison across all study arms
Study NCT06797440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual tasks of digital technology
Description: The intervention activities of this study were cognitive and physical activity training using Nintendo Switch twice a week, 60 minutes each time (5 minutes of warm-up and cool-down exercises, 10 minutes of stretching exercises, and 40 minutes of exercise combined with cognitive training) for a total of 8 weeks. train. Both groups filled in basic data (demographics and disease characteristics) and underwent cognitive function measurements and physical activity function measurements at pretest (T0), 4th week (T1), and 8th week (T2).
Study NCT06795672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Three hours of cognitive rehabilitation per week, performed remotely and independently, using a computerized device, which is pre-programmed based on the patient's needs.
Study NCT06795672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional in-person rehabilitation.
Description: Three hours of in-person cognitive rehabilitation per week using a computerized device.
Study NCT06797167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injections of a filler gel containing cross-linked hyaluronic acid
Description: Vaginal Filler will be administered according to Investigator's judgment and Instruction For Use (IFU) to correct hypotrophy, improve the shape and increase the volume of the female external genital areas (labia majora). Vaginal Filler is a resorbable medical device available in packages containing 2 sterile pre-filled mono-use syringes of 1 ml with pre-assembled plunger rod and backstop, containing 25 mg/g cross-linked hyaluronic acid.~The injection is performed by medical personnel at visit V0 in one or both sides of the superficial subcutaneous layer of the labia majora, along its longitudinal axis.The dosage to be used for the individual case is at the doctor's discretion. An anesthetic may be applied (lidocaine 2% injection only in the cannula access point) to the affected area before the IP injection.~In order to maintain the results achieved, an eventual touch-up could be performed one months after the first treatment in the same areas of the first injection, at visit V2.
Study NCT06793735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation with Virtual Reality
Description: Participants assigned to the experimental group will engage in a six-week telerehabilitation program utilizing two non-immersive Virtual Reality (VR) applications, NeuroNation and The Sims Mobile. These apps are designed to enhance cognitive performance and social cognition skills through interactive and scientifically validated exercises. NeuroNation focuses on improving memory, attention, reasoning speed, and mental flexibility, while The Sims Mobile engages participants in realistic social scenarios that challenge their empathy, communication, and problem-solving abilities. The intervention involves three 30-minute sessions per week, which participants will complete remotely using smartphones or tablets. Therapists will provide weekly virtual check-ins to monitor progress, address questions, and ensure adherence to the protocol. This program aims to create an engaging and accessible rehabilitation experience while promoting real-life application of cognitive and social skills improv
Study NCT06793735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Cognitive Rehabilitation
Description: Participants in the control group will follow a traditional rehabilitation protocol that relies on paper-based cognitive exercises. This program targets cognitive domains such as attention, memory, and executive functions through tasks like puzzles, memory challenges, and problem-solving activities. The intervention also spans six weeks, with participants completing three 30-minute sessions per week. During an initial session, participants will receive all necessary materials and instructions for completing the exercises independently at home. Therapists will provide weekly remote support via phone or video to track progress and address any concerns. This conventional approach serves as a baseline for comparison with the innovative telerehabilitation method in the experimental group.
Study NCT06796946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deprescription of Antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram)
Description: Deprescription of Antidepressants Reduction or elimination of the dose of antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram) taken by patients
Study NCT06795386 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Participants will include people with chronic widespread pain who will undergo bariatric surgery. All participants will receive this intervention and will not be randomized to this or other interventions.
Study NCT06796335 — intervention group
Intervention type: OTHER
Intervention: RIGht
Description: The final intervention consists of five components; 1) education of nurses 2) a dialog tool used in a single session intervention and follow- up 3) a relative- to- relative list 4) video material 5) guidelines on how to document the relative involving plan in the patient's electronic journal.
Study NCT06797739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Description: Patients will be asked to follow the Mediterranean Diet and to participate to an educational program.
Study NCT06797739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Patients will be asked to follow Mediterranean Diet only
Study NCT06793722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Technological device in circumcision
Description: Circumcision is performed by watching a video/playing a game during the procedure in children who are circumcised.
Study NCT06797466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D imaging technique on the PCNL
Description: Establishing a percutaneous access route for the stone is the first and most important step in PCNL surgery. Choosing the perfect route, position and direction largely depends on surgical experience and the ability to understand renal/peri-renal anatomy. In general, a good CT scan of the abdomen and pelvis and an experienced surgeon are sufficient, but this requires significant time in the learning curve. The aim of our study is to investigate the effect of 3D imaging technique on the PCNL learning curve in specialist training.
Study NCT06794996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inaxaplin
Description: Tablets for Oral Administration.
Study NCT06796374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin
Description: A single oral dose of 100 mg fisetin (as Novusetin®) will be administered as 1 capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and fisetin metabolites. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration.
Study NCT06796374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin + Quercetin
Description: A single oral dose of 1000 mg fisetin + 200 mg quercetin will be administered as 2 softgel capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, fisetin metabolites, and quercetin. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration.
Study NCT05806645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk-guided transition of care intervention delivered through an integrated digital health strategy
Description: Patients will receive transition of care plans that are tailored to their medical profile and risk and embedded within standardized discharge pathways within the EHR- Education and self-management guidance about AKI for patients, Medication guidance based on evidence-based indications for reducing risk of cardiac and kidney outcomes, Recommendations for subsequent laboratory testing of kidney function, proteinuria and electrolytes according to clinical characteristics and risks, Recommendations for timing and nature of PCP follow-up, Information about the patient's AKI and subsequent management provided to PCPs through discharge summary, Recommendations for outpatient Pharmacy follow-up for medication reconciliation and review according to patient risk and medication management gaps, Recommendations for Nephrology referral for high risk patients
Study NCT06794034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: taVNS 25Hz+routine treatment, three times daily, 30 mins
Study NCT06794034 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: taVNS 1Hz+routine treatment, three times daily, 30 mins
Study NCT06797817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tributyrin
Description: Participants will receive 1 capsule per day for 12 weeks. Each capsule contains 450 mg of tributyrins. The capsules will have a gelatin coating. In the market, formulations are available with dosages ranging from 200 to 500 mg.
Study NCT06797817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will consist of potato starch encapsulated under identical conditions to those used for the tributyrin capsules, ensuring adequate blinding of the study.
Study NCT06796634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-plasma
Description: * Surgery and application of CAP: at the start of surgery, an inventory is made of suitable tumor nodules that will be planned for resection. Nodules should have a maximal size of 2-3 mm, since it is unlikely that bigger lesions can be adequately treated with CAP.~* Selected tumor nodules will be treated with the J-plasma device at the standard settings (Helium gas flow of 4 l/min, coagulation and cutting intensity at 35). The distance between the tip of the device and the tissue will be approx. 10 mm. Using a timer and footswitch, nodules will be treated at different power settings and durations:~  * 15 W, 30W, or 45W~ * 2, 5, or 10 seconds.~* The treated nodules will be resected at least 30 minutes after plasma treatment, and the exact timing will be documented. The samples are split in half: one half is fixed in formalin for histology and immune histochemistry, and the other half is immediately processed for live/death staining using flow cytometry.
Study NCT06794424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ziwig Endotest®
Description: Saliva sampling for Endometriosis diagnostic
Study NCT06796296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Irrigation (TAI)
Description: The combination of transanal irrigation (TAI) and Loperamide involves administering Loperamide orally, with a daily dosage of 2mg. This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate sysmptoms associated with LARS
Study NCT06792734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTM-3566
Description: Oral Solution
Study NCT06792916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spermidine and minimally invasive non surgical tecnique
Description: minimally non surgical periodontal therapy will be performed with the adjunct of spermidine based gel
Study NCT06792916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peridontal therapy (minimally invasive non surgical tecnique)
Description: subgingival instrumentation will be performed according to MINST
Study NCT05849194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POCUS examination
Description: Point of care ultrasound examination
Study NCT05502081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: antiviral drug
Study NCT05502081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: antiviral drug
Study NCT05580965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 N pressure for 1 minute
Description: After blood collection, 20 N pressure applied for 1 minute
Study NCT05580965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 N pressure for 3 minute
Description: After blood collection, 20 N pressure applied for 3 minute
Study NCT05140304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OCT angiography
Description: OCT angiography of foveal avascular zone in diabetic retinopathy
Study NCT04769596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROMARK™ System
Description: The NEUROMARK™ System is designed to deliver energy to the nasal cavity intended to interrupt nasal nerves aimed to reduce symptoms related to Chronic Rhinitis.
Study NCT06796049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information pamphlet + social norm driver
Description: The information pamphlet is given to participants at the end of the visit. The pamphlet contains an easy-to-read description of FIT screening adapted from the NYC department of health C5 Colorectal cancer (CRC) screening coalition pamphlet and lead-time CRC screening messaging tool, instructions on how to complete the test and the importance of FIT screening.~The information pamphlet will also contain a social norm driver that displays the sub-par screening rate the clinic compared to a collective New York State screening rate and a national screening rate goal set by the CDC.
Study NCT06796049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information pamphlet
Description: The information pamphlet is given to participants at the end of the visit. The pamphlet contains an easy-to-read description of FIT screening adapted from the NYC department of health C5 CRC screening coalition pamphlet and lead-time CRC screening messaging tool, instructions on how to complete the test and the importance of FIT screening.
Study NCT06794749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy
Description: Patients received general physiotherapy in addition to action observation therapy (AOT) via telerehabilitation method for 5 weeks, 3 days a week. AOT was applied to patients as a single session per day and lasted 30 minutes. General physiotherapy session was applied face to face for 45 minutes.
Study NCT06794749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients received general physiotherapy in addition to action observation therapy (AOT) via face-to-face telerehabilitation method for 5 weeks, 3 days a week. AOT was applied to patients as a single session per day and lasted 30 minutes. General physiotherapy session was applied face-to-face for 45 minutes.